Peptonic Medical (publ) (“Peptonic” or “the Company”) has had a highly successful launch of VagiVital Intimate Calming Gel in Sweden, with nearly 1,000 units sold within the first few days. The next step is the launch in Norway, followed by a broad introduction to the U.S. market at the end of March. VagiVital Intimate Calming Gel is a specially developed self-care product that quickly hydrates and soothes irritation, redness, and sensitivity in the external intimate area. The product is a strategically important addition to Peptonic’s growing portfolio of intimate self-care products, further strengthening the Company’s offering of hormone-free, clinically proven treatments for both internal and external intimate care.
The strong initial sales results in Sweden confirm that VagiVital Intimate Calming Gel meets a clear market need. With nearly 1,000 units sold within the first few days, the reception has exceeded expectations. Peptonic is now focused on expanding VagiVital Intimate Calming Gel internationally, with Norway as the next market before the full-scale U.S. launch at the end of March.
The demand for products that hydrate and soothe sensitive skin in the external intimate area is significant, and VagiVital Intimate Calming Gel is a perfect complement to Peptonic’s existing product range. This makes it a strategically important addition to the Company’s growing portfolio of over-the-counter intimate care products.
VagiVital Intimate Calming Gel is available for purchase through pharmacies and the Company’s online store. For more information, please visit: www.vagivital.se.
For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions. The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
